Medical insurance fee control becomes normal, and pharmaceutical companies may take the road of internationalization or have opportunities

[pharmaceutical network market analysis] in recent years, with the continuous promotion of policies such as medical insurance fee control and volume purchase, the industry concentration has been increasing, the pharmaceutical pattern has changed significantly, many pharmaceutical enterprises are under pressure, and they are gradually eliminated or on the way of M & A and becoming pharmaceutical enterprises' processing factories, while the head enterprises are expected to get better development opportunities However, some insiders one pointed out that with one country's "one belt, one road" initiative and the "going global" strategy, the market share of domestic pharmaceutical companies is expanding constantly in the process of internationalization, so there are still great opportunities for pharmaceutical companies to internationalize The author has learned that many domestic pharmaceutical enterprises are really on the road of internationalization In September this year, the Industry Research Report "transformation, growth - the road to transformation of local pharmaceutical enterprises" released by Ernst & Young pointed out that internationalization strategy has become one of the important development strategies of local pharmaceutical enterprises For mature drugs or reagents, local pharmaceutical companies expand product coverage by expanding sales channels, seek new growth, and improve revenue and profits; for innovative drugs, overseas layout is carried out in advance to achieve simultaneous listing of new products at home and abroad In addition to strengthening the main business, many local pharmaceutical enterprises also actively carry out diversified operation, carry out vertical expansion of business segments, and realize diversified layout From the perspective of the current internationalization process of domestic pharmaceutical enterprises, the time of internationalization of raw materials, preparations, R & D and capital is constantly shortened and accelerated For example, Ke Xiao, executive vice president of Kanghong pharmaceutical, said recently that the impact of medical reform on the whole industry is very far-reaching What the company can do is to speed up the pace of internationalization, speed up to the international market to occupy another 90% of the market, which is Kanghong's top priority In addition, Kanghong pharmaceutical is also accelerating the research and development of new products to adapt to the new environment In addition, on March 5 of this year, the stone Pharmaceutical Group issued a notice, successfully submitting a new drug listing application to the U.S FDA for the L-amlodipine maleate tablet for the treatment of hypertension Industry insiders pointed out that there is no precedent for Chinese pharmaceutical enterprises to complete the NDA The new drug listing application submitted by Shiyao group means that Chinese pharmaceutical enterprises have taken a great leap forward in the process of international development At present, some pharmaceutical enterprises rely on the advantages of early APIs to expand overseas markets After years of efforts, they have successfully consolidated the foundation of overseas business and have a deep layout in overseas marketing channels At the same time, with the help of mature international experience, some pharmaceutical enterprises have achieved the overseas increment of high-quality generic drugs in less than 10 years For example, Baiji Shenzhou has been striving to implement the globalization strategy At present, more than 60 clinical trials are being carried out worldwide, including 26 clinical trials registered or expected to be registered The clinical development area covers five continents, including Asia, Australia, North America, Europe, South America, etc., with broad market prospects at home and abroad At the same time, Baiji Shenzhou has also worked with a large number of international pharmaceutical enterprises to actively lay out strategic cooperation in the world, accelerate the development of innovative drugs with potential, and further enrich the product pipeline In general, with the domestic medical insurance fee control becoming the norm, as well as the environmental problems, population pressure and aging trend caused by the improvement of consumption level and the rapid development of modern society, pharmaceutical enterprises may have opportunities to take the road of internationalization The industry believes that Chinese pharmaceutical companies need to constantly break through the transformation of key technologies and improve quality, while exploring a unique way of international development.